### NICEATM

National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods



Interagency Coordinating Committee on the Validation of Alternative Methods



ICCVAM/NICEATM/ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce, and Replace the Mouse LD<sub>50</sub> Assay for Botulinum Toxin Testing

Introduction and Welcome

William S. Stokes, D.V.M., DACLAM RADM, U.S. Public Health Service

> November 13-14, 2006 Crowne Plaza Hotel Silver Spring, MD






**Workshop Organizers and Sponsors** 



- Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
- National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)
- European Centre for the Validation of Alternative Methods (ECVAM)







- To review the state-of-the-science and current knowledge of alternatives that may reduce, replace, and refine (less pain and distress) the use of mice for botulinum toxin testing
- To identify priorities for research, development, and validation efforts needed to advance the use of alternative methods

## **Workshop Objectives - 1**

- Review the public health needs for botulinum toxin testing, including the necessity to determine the safety and efficacy of products containing botulinum toxin (Session 1)
- Review the current state-of-the-science and identify knowledge gaps regarding botulinum toxin structural aspects, mechanisms, and modes of action that are important to the development of alternative methods for *in vivo* botulinum toxin tests, and prioritize future research initiatives that would address these knowledge gaps (Session 2)

ICCVAM

NICEAT


5


# **Workshop Objectives - 2**

Review current development and/or validation 3. status of alternative test methods for in vivo botulinum toxin tests and their potential to reduce, refine (less pain and distress), or replace the use of the mouse LD<sub>50</sub> assay (**Sessions 3, 4, and 5**)

Identify alternative methods that should have the 4. highest priority for future development and validation studies to assess potentcy/toxicity of botulinum toxin(Sessions 3, 4, and 5)

ICCVAM





## **ICCVAM Biologics Working Group**

	CDC	Joanne Andreadis, Ph.D.	FDA	Suzanne Fitzpatrick, Ph.D.
		Susan Maslanka, Ph.D.		Dave Hattan, Ph.D.
				Abby Jacobs, Ph.D.*
	USDA	Donald Kolbe		James Keller, Ph.D.
		Jodie Kulpa-Eddy, D.V.M.*		Richard McFarland, M.D., Ph.D.
				Amy Rosenberg, M.D.
	DOD	Leonard Smith, Ph.D.		Leonard Schechtman, Ph.D.
				Shashi Sharma, Ph.D.
	DOI	Tonie Rocke, Ph.D.		Elizabeth Shores, Ph.D.
				Richard Whiting, Ph.D.
	EPA	Karen Hamernik, Ph.D.		
		Chandrika Moudgal, M.S.	NIEHS	William Stokes, D.V.M.
		Ram Ramabhadran, Ph.D.		Raymond Tice, Ph.D.
		Amy Rispin, Ph.D.		
			ECVAM	Marlies Halder, Ph.D.
	* Working Group Co-Chairs			
)		3		

10

## **NICEATM Staff**

#### **NIEHS**

William S. Stokes, D.V.M.,DACLAM Raymond Tice, Ph.D. Debbie McCarley Director; Project Officer Deputy Director; Asst. Project Officer Special Assistant; Asst. Project Officer

#### Center Support Contract (ILS, Inc.)

David Allen, Ph.D. Thomas Burns, M.S. Patricia Ceger, M.S. Neepa Choksi, Ph.D. Frank Deal, M.S. Elizabeth Lipscomb, Ph.D. Linda Litchfield Michael Paris Judy Strickland, Ph.D., DABT Jim Truax, M.A. Doug Winters, M.S. Senior Toxicologist/Principal Investigator Sr. Project Coordinator/Technical Writer Project Coordinator/Technical Writer Sr. Staff Toxicologist Staff Toxicologist Staff Toxicologist Administrative Asst./Meeting Planner Sr. Project Coordinator/Technical Writer Sr. Staff Toxicologist Project Coordinator Project Manager

ICCVAM

NICEATM

11